Exclusive-Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say
By Foo Yun Chee BRUSSELS (Reuters) -Teva, the world’s largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday. The European Commission in 2022 charged the Israeli company …








